Literature DB >> 1957125

Klebsiella bacteremia: a review of 196 episodes during a decade (1980-1989).

C Watanakunakorn1, J Jura.   

Abstract

This report reviews 196 episodes of klebsiella bacteremia in 194 patients during a 10-year period (1980-1989) in a community teaching hospital in the USA. The median age of patients was 70 years with a mode of 84 years. The prevalence was 0.76 episodes/1000 admissions. Nosocomial acquisition of bacteremia occurred in 43% of episodes and 16% of patients were from nursing homes. Klebsiella pneumoniae accounted for 86% and K. oxytoca for 13% of episodes. Most isolates were resistant to ampicillin and carbenicillin but susceptible to other antimicrobial agents tested. 55 episodes (28%) were polymicrobial; Escherichia coli and enterococci were the most common co-isolates. The major portals of entry were the respiratory tract and urinary tract. The majority of patients had major underlying conditions. The overall mortality was 37%. Factors that adversely influenced the mortality rate were nosocomial bacteremia, polymicrobial bacteremia, respiratory tract as the portal of entry, rapidly fatal and ultimately fatal underlying conditions, septic shock, severe leukopenia, increases in total serum bilirubin level or serum creatinine level and inappropriate antimicrobial therapy.

Entities:  

Mesh:

Year:  1991        PMID: 1957125     DOI: 10.3109/00365549109075086

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  8 in total

1.  Identification of clinical isolates of indole-positive and indole-negative Klebsiella spp.

Authors:  Maria Silvana Alves; Rubens Clayton da Silva Dias; Angela Christina Dias de Castro; Lee W Riley; Beatriz Meurer Moreira
Journal:  J Clin Microbiol       Date:  2006-08-23       Impact factor: 5.948

Review 2.  Klebsiella oxytoca and Emerging Nosocomial Infections.

Authors:  Nakul Neog; Upasana Phukan; Minakshi Puzari; Mohan Sharma; Pankaj Chetia
Journal:  Curr Microbiol       Date:  2021-03-03       Impact factor: 2.188

3.  Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points.

Authors:  Kerri A Thom; Michelle D Shardell; Regina B Osih; Marin L Schweizer; Jon P Furuno; Eli N Perencevich; Jessina C McGregor; Anthony D Harris
Journal:  Infect Control Hosp Epidemiol       Date:  2008-11       Impact factor: 3.254

4.  Recommended test panel for differentiation of Klebsiella species on the basis of a trilateral interlaboratory evaluation of 18 biochemical tests.

Authors:  Dennis S Hansen; Hazel M Aucken; Titi Abiola; Rainer Podschun
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

5.  Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance.

Authors:  Cheol-In Kang; Sung-Han Kim; Ji-Whan Bang; Hong-Bin Kim; Nam-Joong Kim; Eui-Chong Kim; Myoung-don Oh; Kang-Won Choe
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

6.  Characteristics of a Bacteriophage, vB_Kox_ZX8, Isolated From Clinical Klebsiella oxytoca and Its Therapeutic Effect on Mice Bacteremia.

Authors:  Ping Li; Yangheng Zhang; Fuhua Yan; Xin Zhou
Journal:  Front Microbiol       Date:  2021-12-03       Impact factor: 5.640

7.  Differences in characteristics between healthcare-associated and community-acquired infection in community-onset Klebsiella pneumoniae bloodstream infection in Korea.

Authors:  Younghee Jung; Myung Jin Lee; Hye-Yun Sin; Nak-Hyun Kim; Jeong-Hwan Hwang; Jinyong Park; Pyoeng Gyun Choe; Wan Beom Park; Eu Suk Kim; Sang-Won Park; Kyoung Un Park; Hong Bin Kim; Nam-Joong Kim; Eui-Chong Kim; Kyoung-Ho Song; Myoung-Don Oh
Journal:  BMC Infect Dis       Date:  2012-10-03       Impact factor: 3.090

8.  Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study.

Authors:  Kerri A Thom; Marin L Schweizer; Regina B Osih; Jessina C McGregor; Jon P Furuno; Eli N Perencevich; Anthony D Harris
Journal:  BMC Infect Dis       Date:  2008-09-15       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.